Drugs / AUTO3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03287817 | Sep 2017 → Oct 2023 | relapsed/refractory diffuse large B-cell lymphoma | Autolus Limited | Terminated | No outcome recorded |
| Phase 1/2 | NCT03289455 | Jun 2017 → May 2020 | B-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Autolus Limited | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUTO3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03289455 ↗ |
| Modality | Cell therapy | “AUTO3, a CAR T cell treatment targeting CD19 and CD22” NCT03287817 ↗ |
| Route | Intravenous | “the patient will receive AUTO 3 intravenously as a single dose” NCT03287817 ↗ |
| Target | CD19 | “targeting CD19 and CD22” NCT03289455 ↗ |
| Target | CD22 | “targeting CD19 and CD22” NCT03289455 ↗ |